Authors

Latest:

Biomarkers Predict Prognosis for Patients With mCRPC

A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with metastatic castration-resistant prostate cancer

Patricia Ganz, MD

Latest:

Dr. Ganz on the Quality of Life Results From the OlympiA Trial in BRCA-Mutated Breast Cancer

Patricia A. Ganz, MD, discusses the quality of life results from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Patricia J. Goldsmith

Latest:

Patricia Goldsmith on Financial Stress Associated With Cancer Care

Patricia J. Goldsmith, chief executive officer, CancerCare, previews data of a CancerCare study highlighting some of the financial challenges associated with patients who have cancer.

Patricia LoRusso, DO

Latest:

Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated Liposarcoma

Patricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.

Patricia M. LoRusso, DO

Latest:

Dr. LoRusso on the Benefit of Genetic Sequencing in Sarcomas

Patricia LoRusso, DO, discusses the benefit of genetic sequencing in soft tissue sarcomas.

Patricia S. Hofstra

Latest:

Patricia Hofstra on Alternatives to Acquisition in Healthcare

Patricia Hofstra, attorney, Duane Morris, discusses options that independent oncology groups have other than being acquired by larger healthcare or oncology systems.

Patrick A. Ott, MD, PhD

Latest:

Immune Checkpoint Blockade in Cancer: Inhibiting CTLA-4 and PD-1/PD-L1 With Monoclonal Antibodies

Inhibitory receptors such as anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) expressed on tumor-specific T cells lead to compromised activation and suppressed effector functions such as proliferation, cytokine secretion, and tumor cell lysis.

Patrick Borgen, MD

Latest:

Leveraging Genomic Assays to Guide Treatment Decisions: Clinical Scenarios and Expert Perspectives

Panelists discuss how genomic testing informs real clinical scenarios, demonstrating that for a 64-year-old healthy woman with a single positive lymph node, the 21-gene assay would guide treatment decisions, with cardiac assessment influencing whether anthracycline-based chemotherapy would be used if her score was high.

Patrick Brown, MD

Latest:

Dr. Brown on the Success of Blinatumomab in the AALL 1331 Trial

Patrick Brown, MD, discusses the encouraging results of blinatumomab (Blincyto) in the AALL1331 trial.

Patrick C. Walsh, MD

Latest:

Dr. Walsh Compares Open and Robotic-Assisted Radical Prostatectomy Operations

Patrick C. Walsh, MD, university distinguished service professor of urology, Johns Hopkins School of Medicine, discusses radical prostatectomy operations in the traditional open and robotic-assisted form.

Patrick Cobb, MD, FACP

Latest:

How Does IT Affect Quality of Care?

Oncology practices across the country are using computer technology to improve outcomes and quality of care for our patients.

Patrick I. Borgen, MD

Patrick I. Borgen, MD is the chair of the Department of Surgery and head of the Maimonides Breast Center at Maimonides Medical Center.

Latest:

Dr Borgen on the Need for Improved Risk Stratification in Early-Stage Breast Cancer

Patrick I. Borgen, MD, discusses the need for improved risk stratification in early-stage breast cancer.

Patrick M. Forde, MBBCh

Latest:

Dr. Forde on Updates to the TNM Staging System in Lung Cancer

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses updates to the tumor, node, metastasis (TNM) staging system in lung cancer.

Patrick Neven, MD, PhD

Latest:

Dr. Neven on the Relationship of Cell Cycle Genes and Outcomes in HR+/HER2– Breast Cancer

Patrick Neven, MD, discusses the association between cell cycle–related genes and outcomes for patients with hormone receptor–positive/HER2-negative advanced breast cancer treated on the phase 3 MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials.

Patrick Ott, MD, PhD

Latest:

Dr. Ott Discusses Ipilimumab and Nivolumab in Melanoma

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses ipilimumab (Yervoy) and nivolumab (Opdivo) both in combination and as a monotherapy for patients with melanoma.

Patrick Schoffski, MD

Latest:

Dr. Schoffski Discusses Findings from the CREATE Study

Patrick Schöffski, MD, MPH, head of the Department of General Medical Oncology at the University Hospital Leuven, discusses the findings from the CREATE study during the 2018 AACR Annual Meeting.

Patrick W. Cobb, MD

Latest:

Dr. Cobb on the Complications of Reimbursement in Oncology

Dr. Patrick Cobb from the Community Oncology Alliance on the Complications of Reimbursement in Oncology

Patrick W. Whitworth, MD

Latest:

Preventing Clinical Lymphedema With Bioimpedance Spectroscopy

Employing preclinical detection using bioimpedance spectroscopy, breast centers are reporting progression to clinical lymphedema in less than 10% of patients at high risk of developing the condition.

Paul A. Bunn Jr, MD

Latest:

Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLC

Paul A. Bunn, Jr, MD, highlights encouraging data with fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Paul A. Bunn, MD

Latest:

Dr. Bunn on Targeting HER3 in NSCLC

Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.